Amarin Corp Plcuk (AMRN) Gross Margin (2013 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Gross Margin of 39.37% for Q1 2026, down 2044.0% YoY from 2.03% in Q1 2025, and down 16.36% sequentially from 47.07% in Q4 2025.
Amarin Corp Plcuk (AMRN) Gross Margin (2013 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Gross Margin across 14 years of filings, most recently posting 39.37% for Q1 2026.
- In Q1 2026, Gross Margin fell 2044.0% year-over-year to 39.37%; the TTM figure through Mar 2026 stood at 52.37% (up 1752.0% YoY), while the FY2025 annual figure was 56.57%, up 2098.0% from the prior year.
- Gross Margin fell to 39.37% in Q1 2026, from 47.07% in the prior quarter.
- Over the last five years, Gross Margin for AMRN reached as high as 76.5% in Q1 2022 and fell as low as 15.35% in Q4 2024.
- The 5-year median for Gross Margin is 55.75% (2023), against an average of 51.81%.
- Annual changes were most pronounced in 2024 — Gross Margin tumbled 7575 bps — and 2025, when it soared 6243 bps.
- A 5-year view of Gross Margin shows it stood at 70.48% in 2022, then slipped by 14 bps to 60.4% in 2023, then slumped by 125 bps to 15.35% in 2024, then jumped by 407 bps to 47.07% in 2025, then dropped by 16 bps to 39.37% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 39.37%, 47.07%, and 44.71% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 81.93% |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 66.31% |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 71.88% |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 87.65% |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 74.24% |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 68.16% |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 79.24% |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -51.69% |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | 39.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 39.37% |
| Dec 31, 2025 | 47.07% |
| Sep 30, 2025 | 44.71% |
| Jun 30, 2025 | 69.23% |
| Mar 31, 2025 | 59.81% |
| Dec 31, 2024 | -15.35% |
| Sep 30, 2024 | 38.48% |
| Jun 30, 2024 | 63.37% |
| Mar 31, 2024 | 56.45% |
| Dec 31, 2023 | 60.40% |
| Sep 30, 2023 | 45.15% |
| Jun 30, 2023 | 53.22% |
| Mar 31, 2023 | 55.75% |
| Dec 31, 2022 | 70.48% |
| Sep 30, 2022 | 69.94% |
| Jun 30, 2022 | 46.20% |
| Mar 31, 2022 | 76.50% |
| Dec 31, 2021 | 78.80% |
| Sep 30, 2021 | 78.73% |
| Jun 30, 2021 | 79.19% |